In accordance with these results, we reported, in HMCLs, a synergistic anti-tumor effect by combining NEAT1 silencing and the PARP (poly ADP-ribose polymerase) inhibitor olaparib, known to induce synthetic lethality in tumors with HR deficiency. This evidence concerns the gene NEAT1 and neoplasm.